Curative Biotechnology Inc
Research Curative Biotechnology Inc (CUBT) on Bullrun: market cap USD 8.45M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCUBT
- ExchangeNYSE MKT
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 8.45M
- Financial periodQ1 2023
- RevenueUSD 0
- Net income-USD 5.17M
- Free cash flow-USD 534.89K
Valuation Snapshot
latest market cap is USD 8.45M.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 8.45M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 868.94M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.76B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.01B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.61B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 4.36B | n/a | n/a | n/a |
About Curative Biotechnology Inc
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Curative Biotechnology Inc's market cap?
Curative Biotechnology Inc's market capitalization is USD 8.45M.
What does Curative Biotechnology Inc do?
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor.